Literature DB >> 28499669

Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome.

Yuichiro Yamada1, Shino Takeuchi2, Mamoru Yoneda1, Shogo Ito1, Yusuke Sano1, Kai Nagasawa1, Natsumi Matsuura1, Ayako Uchinaka1, Toyoaki Murohara3, Kohzo Nagata4.   

Abstract

BACKGROUND: Statins are strong inhibitors of cholesterol biosynthesis and help to prevent cardiovascular disease. They also exert additional pleiotropic effects that include an anti-inflammatory action and are independent of cholesterol, but the molecular mechanisms underlying these additional effects have remained unclear. We have now examined the effects of atorvastatin on cardiac and adipose tissue inflammation in DahlS.Z-Leprfa/Leprfa (DS/obese) rats, which we previously established as a model of metabolic syndrome (MetS). METHODS AND
RESULTS: DS/obese rats were treated with atorvastatin (6 or 20mgkg-1day-1) from 9 to 13weeks of age. Atorvastatin ameliorated cardiac fibrosis, diastolic dysfunction, oxidative stress, and inflammation as well as adipose tissue inflammation in these animals at both doses. The high dose of atorvastatin reduced adipocyte hypertrophy to a greater extent than did the low dose. Atorvastatin inhibited the up-regulation of peroxisome proliferator-activated receptor γ gene expression in adipose tissue as well as decreased the serum adiponectin concentration in DS/obese rats. It also activated AMP-activated protein kinase (AMPK) as well as inactivated nuclear factor-κB (NF-κB) in the heart of these animals. The down-regulation of AMPK and NF-κB activities in adipose tissue of DS/obese rats was attenuated and further enhanced, respectively, by atorvastatin treatment.
CONCLUSIONS: The present results suggest that the anti-inflammatory effects of atorvastatin on the heart and adipose tissue are attributable at least partly to increased AMPK activity and decreased NF-κB activity in this rat model of MetS.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AMP-activated protein kinase; Atorvastatin; Inflammation; Metabolic syndrome; Nuclear factor–κB

Mesh:

Substances:

Year:  2017        PMID: 28499669     DOI: 10.1016/j.ijcard.2017.04.103

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  13 in total

1.  Asymptomatic Left Ventricular Hypertrophy Is a Potent Risk Factor for the Development of HFpEF but Not HFrEF: Results of a Retrospective Cohort Study.

Authors:  Artem Ovchinnikov; Evgeny Belyavskiy; Alexandra Potekhina; Fail Ageev
Journal:  J Clin Med       Date:  2022-07-04       Impact factor: 4.964

2.  Investigation into potential mechanisms of metabolic syndrome by integrative analysis of metabolomics and proteomics.

Authors:  Meimei Chen; Zhaoyang Yang; Huijian Gan; Yang Wang; Chandong Li; Yuxing Gao
Journal:  PLoS One       Date:  2022-07-05       Impact factor: 3.752

3.  Anti-inflammatory effects of heat-killed Lactobacillus plantarum L-137 on cardiac and adipose tissue in rats with metabolic syndrome.

Authors:  Ayako Uchinaka; Naoki Azuma; Hisashi Mizumoto; Shiho Nakano; Moeko Minamiya; Mamoru Yoneda; Kiyoshi Aoyama; Yuki Komatsu; Yuichiro Yamada; Toyoaki Murohara; Kohzo Nagata
Journal:  Sci Rep       Date:  2018-05-25       Impact factor: 4.379

4.  Monotherapy of experimental metabolic syndrome: I. Efficacy and safety.

Authors:  Štefan Bezek; Zuzana Brnoliaková; Ružena Sotníková; Vladimír Knezl; Ema Paulovičová; Jana Navarová; Viktor Bauer
Journal:  Interdiscip Toxicol       Date:  2018-02-14

5.  Statins Reduce Epicardial Adipose Tissue Attenuation Independent of Lipid Lowering: A Potential Pleiotropic Effect.

Authors:  Paolo Raggi; Varuna Gadiyaram; Chao Zhang; Zhengjia Chen; Gary Lopaschuk; Arthur E Stillman
Journal:  J Am Heart Assoc       Date:  2019-06-13       Impact factor: 5.501

6.  PCSK9 inhibitor and atorvastatin reduce cardiac impairment in ovariectomized prediabetic rats via improved mitochondrial function and Ca2+ regulation.

Authors:  Patchareeya Amput; Siripong Palee; Busarin Arunsak; Wasana Pratchayasakul; Chanisa Thonusin; Sasiwan Kerdphoo; Thidarat Jaiwongkam; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  J Cell Mol Med       Date:  2020-07-06       Impact factor: 5.310

Review 7.  Inflammatory Cytokines, Immune Cells, and Organ Interactions in Heart Failure.

Authors:  Huihui Li; Chen Chen; Dao Wen Wang
Journal:  Front Physiol       Date:  2021-07-01       Impact factor: 4.566

Review 8.  Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction.

Authors:  Domenico D'Amario; Stefano Migliaro; Josip A Borovac; Attilio Restivo; Rocco Vergallo; Mattia Galli; Antonio Maria Leone; Rocco A Montone; Giampaolo Niccoli; Nadia Aspromonte; Filippo Crea
Journal:  Front Physiol       Date:  2019-11-05       Impact factor: 4.566

Review 9.  Obesity and Atrial Fibrillation: Should We Screen for Atrial Fibrillation in Obese Individuals? A Comprehensive Review.

Authors:  Kyrillos N Ghattas; Shahbakht Ilyas; Reham Al-Refai; Reeju Maharjan; Liliana Diaz Bustamante; Safeera Khan
Journal:  Cureus       Date:  2020-09-15

10.  Alleviation of salt-induced exacerbation of cardiac, renal, and visceral fat pathology in rats with metabolic syndrome by surgical removal of subcutaneous fat.

Authors:  Kiyoshi Aoyama; Yuki Komatsu; Mamoru Yoneda; Shiho Nakano; Sao Ashikawa; Yumeno Kawai; Xixi Cui; Katsuhide Ikeda; Kohzo Nagata
Journal:  Nutr Diabetes       Date:  2020-08-10       Impact factor: 5.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.